{"transactions":[{"id":1791159,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":110055,"kind":"person","name":"Miller Seline E.","position":1,"cik":"0001769866","reported_name":"Miller Seline E.","relationship":{"officer":true,"officer_title":"SVP Finance; Interim CFO & PAO"}}],"security":"Series Y Preferred Stock","published_at":"2023-09-01T20:07:11.000Z","date":"2023-08-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On June 20, 2023, the Company's board of directors (the \"Board\") declared a dividend of one one-thousandth of a share of Series Y Preferred Stock, par value $0.001 per share (the \"Preferred Stock\"), for each outstanding share of common stock to common stockholders of record at 5:00 p.m. Eastern Time on June 30, 2023, in a transaction exempt from Section 16 under Rule 16a-9. The shares of Preferred Stock were distributed on June 30, 2023. As a result, the Reporting Person received the shares of Preferred Stock set forth above. The Preferred Stock was not convertible into, or exchangeable for, shares of any other class or series of stock or other securities of the Company"},{"field":"shares","element":"transactionShares","label":"F2","text":"On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 31, 2023, the Company filed, as approved by the Board, a certificate of elimination with the Secretary of State of the State of Delaware pursuant to which the outstanding shares of the Preferred Stock were eliminated."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001140361-23-042369","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000114036123042369/form4.xml","form_type":"4"}},{"id":2189842,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":110055,"kind":"person","name":"Miller Seline E.","position":1,"cik":"0001769866","reported_name":"Miller Seline E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Finance; Interim CFO & PAO"}}],"security":"Common Stock","published_at":"2022-08-10T21:19:12.000Z","date":"2022-08-09","kind":"purchase","acquired":true,"shares":3250,"price":0.47,"value":1527.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on August 9, 2022."}],"balance_after":6500,"source":{"system":"sec-edgar","filing":"0001209191-22-045254","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919122045254/doc4.xml","form_type":"4"}},{"id":2379263,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":110055,"kind":"person","name":"Miller Seline E.","position":1,"cik":"0001769866","reported_name":"Miller Seline E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Finance; Interim CFO & PAO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-02-23T21:08:08.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":107500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4 of the shares subject to the option will vest on the one-year anniversary of the vesting commencement date of February 11, 2022, and 1/48 of the shares subject to the option will vest on each monthly anniversary of the vesting commencement date thereafter."}],"balance_after":107500,"derivative":{"exercise_price":0.52,"expiration_date":"2032-02-11","underlying":"Common Stock","underlying_shares":107500},"source":{"system":"sec-edgar","filing":"0001209191-22-012159","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919122012159/doc4.xml","form_type":"4"}},{"id":2392351,"issuer":{"id":5247,"kind":"organization","name":"GYRE THERAPEUTICS, INC."},"owners":[{"id":110055,"kind":"person","name":"Miller Seline E.","position":1,"cik":"0001769866","reported_name":"Miller Seline E.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP Finance; Interim CFO & PAO"}}],"security":"Common Stock","published_at":"2022-02-17T01:10:43.000Z","date":"2022-02-09","kind":"purchase","acquired":true,"shares":3250,"price":0.46,"value":1495.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Shares purchased under the Issuer's 2018 Employee Stock Purchase Plan on February 9, 2022."}],"balance_after":3250,"source":{"system":"sec-edgar","filing":"0001209191-22-010403","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1124105/000120919122010403/doc4.xml","form_type":"4"}}]}